Meetings: FIFRA Scientific Advisory Panel

Comments

Total: 52
Comment submitted by Lawrence E. Culleen, Arnold & Porter LLP
Posted : 11/25/2011     ID :EPA-HQ-OPP-2011-0718-0049     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Todd Butzow, Bell Laboratories, Inc
Posted : 11/25/2011     ID :EPA-HQ-OPP-2011-0718-0050     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Lawrence E. Culleen, Arnold & Porter
Posted : 11/25/2011     ID :EPA-HQ-OPP-2011-0718-0051     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Beth L. Law, CSPA
Posted : 12/05/2011     ID :EPA-HQ-OPP-2011-0718-0066     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Bill Mordan, Reckitt Benckiser
Posted : 12/07/2011     ID :EPA-HQ-OPP-2011-0718-0067     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Ahna Brutlag, DVM, MS
Posted : 12/07/2011     ID :EPA-HQ-OPP-2011-0718-0068     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Richard Kingston, Pharm D
Posted : 12/12/2011     ID :EPA-HQ-OPP-2011-0718-0069     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by James McCluskey, MD, PhD, MPH
Posted : 12/12/2011     ID :EPA-HQ-OPP-2011-0718-0070     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Anne Fairbrother, DVM, PhD
Posted : 12/12/2011     ID :EPA-HQ-OPP-2011-0718-0071     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Richard K. Stroud, DVM, MS
Posted : 12/12/2011     ID :EPA-HQ-OPP-2011-0718-0072     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Alan Buckle, PhD
Posted : 12/12/2011     ID :EPA-HQ-OPP-2011-0718-0073     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Hans-Joachim Pelz, PhD
Posted : 12/12/2011     ID :EPA-HQ-OPP-2011-0718-0074     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Richard L. Wade, PhD., M.P.H
Posted : 12/12/2011     ID :EPA-HQ-OPP-2011-0718-0075     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Colin Prescott, PhD
Posted : 12/12/2011     ID :EPA-HQ-OPP-2011-0718-0076     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Lawrence Cullen, Arnold and Palmer
Posted : 12/12/2011     ID :EPA-HQ-OPP-2011-0718-0077     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Peter Batten, Reckitt Benckiser
Posted : 12/15/2011     ID :EPA-HQ-OPP-2011-0718-0078     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Stefano M. Costanzo, Exponent, Inc., Reckitt Benckiser, Brodifacoum Probabilistic Risk Assessment
Posted : 12/16/2011     ID :EPA-HQ-OPP-2011-0718-0079     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Tom Parshley, Syngenta, Reckitt Benckiser, Industry reponse to EPA review of Brodifacoum Probabilistic Risk Assessment
Posted : 12/16/2011     ID :EPA-HQ-OPP-2011-0718-0080     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Iraida Afanador, City of Camden NJ, Letter: City of Camden NJ - Received after close of public comment period.
Posted : 12/16/2011     ID :EPA-HQ-OPP-2011-0718-0081     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Lawrence E. Culleen, Arnold & Porter on behalf of Reckitt Benckiser, Letter: Culleen to Bradbury/Portier - Received after close of public comment period
Posted : 12/16/2011     ID :EPA-HQ-OPP-2011-0718-0082     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Lawrence E. Culleen, Arnold & Palmer on behalf of Reckitt Benckiser,Reckitt Benckiser - SAP - REVISED Volume 7. Effect of Formulation on Efficacy - Received after close of public comment period.
Posted : 12/16/2011     ID :EPA-HQ-OPP-2011-0718-0083     Agency : EPA

Nov 28,2011 11:59 PM ET
Comment submitted by Reckitt Benckiser
Posted : 12/19/2011     ID :EPA-HQ-OPP-2011-0718-0084     Agency : EPA

Nov 28,2011 11:59 PM ET